Premium
Oral allergy syndrome: the effect of astemizole
Author(s) -
BindslevJensen C.,
Vibits A.,
Skov P. Stahl,
Weeke B.
Publication year - 1991
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.1991.tb00631.x
Subject(s) - astemizole , medicine , placebo , allergy , oral allergy syndrome , ingestion , histamine , basophil activation , histamine h1 receptor , anaphylaxis , gastroenterology , anesthesia , basophil , immunology , immunoglobulin e , alternative medicine , antibody , pathology , receptor , antagonist
The effect of treatment with astemizole (Hismanal®) on symptoms elicited by ingestion of hazelnuts in birch pollen‐allergic patients (the oral allergy syndrome) was investigated. Thirty patients with a well‐documented allergy to silver birch, experiencing symptoms when ingesting hazelnuts, were included in the study. All had a positive skin prick test (SPT) to birch, whereas 29 and 27, respectively, showed a positive RAST and basophil histamine release test (HR) to birch. In contrast, only 15 patients had a positive SPT to hazelnut, 13 had a positive RAST, whereas 24 had a positive HR. Alter two oral provocations with hazelnuts the patients were randomized to receive either 10 mg of astemizole or placebo daily for 2 weeks in a double blind protocol followed by two oral provocations. Treatment with astemizole significantly reduced the symptoms compared with placebo ( P = 0.004); however, without completely abolishing the symptoms.